• Targeted genetic testing of many known hereditary types of cancer
  • Large number of multi-gene NGS panels for various types of cancer
  • Comprehensive genomic testing of all known human cancer genes, leads in a single step to a considerable increase in diagnostic yield for cancer disorders

InterGenetics is continuously developing molecular genetic tests for various cancers, such as breast and ovarian cancer, colon cancer, cancer of the thyroid, etc.

Recently, the genetic investigation of cancers has been strengthened through the introduction of new genomic technologies that allow the massive analysis of tens or hundreds of genes known to be associated with various forms of cancer.

The particular advantage of this group of tests is that they are complemented by parallel clinical genetic evaluation and genetic counseling, offered to individuals and families who are burdened with these diseases and in close cooperation with the attending physician, resulting in a complete solution and management of these cases, according to international standards.

General information

Cancer is a very heterogeneous disease, resulting from accumulation of mutations in the DNA. The etiology of cancer is multifactorial, involving genetic, environmental and other medical factors as well as lifestyle factors that interact to develop a specific malignancy.

About 5% -10% of cancers are hereditary and genetic testing has been used for certain hereditary forms of cancer for more than a decade.

The knowledge of the genetics of cancer improves rapidly with the understanding of the molecular mechanisms, which help to identify individuals at high risk, enables characterization of the disease, allows for customized treatments adapted to the molecular basis of the disease, and leading to the development of new therapies.

This expansion of knowledge has implications for all aspects of cancer management, including prevention, detection and treatment.

The percentage of people carrying a pathogenic mutation and who will eventually develop the disease is referred to as penetrance.

Generally, common genetic variants-mutations associated with a predisposition to cancer have a low penetrance compared to rare pathogenic mutations. The precise identification of individuals and families, who are at increased risk of developing cancer, is an important purpose of primary health care.

Once these individuals are identified, they can be evaluated further, through appropriate genetic counseling, in relation to the risks and the required genetic testing, which will lead to the implementation of a personalized management strategy.

Until recently, the most widely used method for the genetic testing of hereditary cancers was the analysis by Sanger DNA sequencing, which is considered the ‘golden standard’ for detecting mutations.

Nevertheless, because the genes associated with hereditary forms of cancer are very large and there are no specific mutation hot spots, this traditional method has generally proven to be time consuming, costly and with a moderate to low diagnostic yield .

Genomic testing in cancer cases offers timely diagnosis, disease prognosis and therapy

Due to the now recognized high degree of genetic heterogeneity of cancers, recent technological developments afford the application of genomic testing, through the simultaneous massive parallel analysis of tens to hundreds of genes by Next Generation Sequencing (NGS), leading in one step to the parallel detection of mutations in multiple genes, which we now know to be associated with various types of cancer in humans.

Generally, these genes include both those associated with hereditary cancers (germline mutations), but also those associated with somatic mutations (i.e. mutations present only in the affected tissue/tumor), all being associated with disease prognosis and/or possible treatment.

Keeping abreast with the latest diagnostic developments in this field, InterGenetics has developed and offers massive parallel genomic testing through Next Generation Sequencing (NGS), for several types of cancers associated with multiple genes, such as genomic testing for breast cancer (19 genes)genomic testing for uterine cancer (20 genes)genomic testing for hereditary non-polyposis colon cancer (8 genes)genomic testing for gastrointestinal cancers (21 genes)genomic testing for pancreatic cancer (12 genes)genomic testing for renal cancers (18 genes), etc..

In addition, we perform and offer massive parallel genomic testing of 400 genes, now known to be associated with all human cancers.

InterGenetics still provides genetic testing based on classic Sanger sequencing for certain types of cancer associated with 1-2 genes, such as breast cancer (BRCA1 and BRCA2)multiple endocrine neoplasia, etc..

Tests included in the group